Media & Technology
Western Magnesium Corp (OTCMKTS: MLYF) Powerful Runner as Magnesium Pioneer Looks to Become the World’s Low-Cost Producer of Green, Pure Magnesium
Western Magnesium Corp (OTCMKTS: MLYF) is making a historic rise up the charts in recent months from well under a dime to recent highs near $1 mark. MLYF is quickly emerging as a volume leader in small caps attraction legions of new shareholders including some heavy hitters on the OTC. Currently under heavy accumulation MLYF is moving steadily northbound with many new investors buying in every day. The stock is a powerhouse and continues to move northbound with strength and purpose.
The Company is focused on becoming the become world’s low-cost producer of eco-friendly, high-quality magnesium. MLYF has created a proprietary technology which creates a purer form of magnesium in contrast to the Pidgeon process which results in a less pure magnesium. Western Magnesium has just completed the buildout its magnesium reactor. This is a significant, and much anticipated milestone for the Company. Executive Chairman, Mr. Ed Lee, states “This reactor unit is a significant step forward that will enable the Company to enter the marketplace with its proprietary continuous condenser, and will secure Western Magnesium’s future for decades to come.” Initial metal production will allow management to work closely with end users in the automotive, aerospace, and ecofriendly technology companies and the Department of Defense to assess the amount of metal needed for their assembly line manufacturing, and the form in which they will need the metal.
Western Magnesium Corp (OTCMKTS: MLYF) (TSXV:WMG) (Frankfurt-3WM) goal is to be a low-cost producer of green, primary magnesium metal, a strategic commodity prized for its strength and light weight. Unlike outdated and costly production processes, Western Magnesium looks to use a continuous silicothermic process to produce 99.9% pure magnesium, which significantly reduces labor and energy costs relative to current methods and processes, while being environmentally friendly. Technology is at the heart of Western Magnesium’s business and is the result of 10 years of stealth research and development done at its original location in British Columbia, Canada. The Company’s R&D team consists of world leading authorities in magnesium production and expertise as well as research from as early as post-WWII U.S. magnesium production; when America led the industry. The Company has been raising money in several private placements and offerings in recent months for proceeds of well over $5 million usd.
MLYF has created a proprietary technology which creates a purer form of magnesium in contrast to the Pidgeon process which results in a less pure magnesium. The Company’s technology overcomes the inefficiency of current production methods that require large quantities of resources, are time consuming, high-risk, and very labor intensive. MLYF proprietary technology utilizes a continuous silicothermic process to produce (99.8%) pure magnesium. The process begins with mined dolomite (calcium-magnesium carbonate), which is crushed and calcined (thermal decomposition) to make Magnesium Oxide (MgO). The MgO is combined with ferrosilicon, a reductant and a catalyst, and formed into briquettes. The briquettes are fed into the newly designed continuous reactor, where they are heated. This allows the silicon to react with oxygen and reduce the magnesium to metal. The vaporized Mg is collected and removed using a proprietary Mg-recovery system designed specifically for this process as molten Mg. The Company’s uses significantly less energy as nature eliminates the temperature cycles. The company uses electric-powered calciner, heat-recovery systems and a method for recovering CO2 from the calcination step which further reduces the environmental footprint and raises efficiency.
https://twitter.com/PennyHo9/status/1422605477997912064
https://twitter.com/JrMagnesium/status/1422734425981296641
To Find out the inside Scoop on MLYF Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
Western Magnesium has recently completed the buildout its magnesium reactor. This is a significant, and much anticipated milestone for the Company, and has accelerated the Company’s internal timeline for the production of magnesium metal. As we have previously focused on metal production by the end of 2021. Testing will commence within the next 30 days, on its proprietary new reactor. Management is pleased with the progress to date and is excited to commence this next phase. Currently the commercialized pilot plant is undergoing the final build out stage and all necessary equipment and supplies have been finalized and ordered, allowing the operations team to produce an updated baseline schedule. Management and staff have been working diligently to expedite this testing phase and we are confident that we will be able to commence production with the new timeline. Ancillary feed equipment has arrived at the facility and has begun operating, allowing the operations team to begin optimizing the feed material composition and size.
This furnace will be the first of its kind, and a major step towards being able to operate a silicothermic reactor system from open atmosphere to a sealed vacuum space on a continuous basis. This is very disruptive technology with controllable parameters from an efficiency, energy, and environmental standpoint. A continuous internally heated reduction furnace of this nature coupled with the proprietary Western Magnesium condenser will allow for maximum continuous production from pit or stockpile, to magnesium metal, to the end-user in timely manner. A process that assembly line manufacturers have longed for.
A third lighter than aluminum, 60% lighter than titanium and 75% lighter than steel, magnesium’s strength and castability has made it an obvious replacement for any component that needs to be lighter and stronger. As the lightest of all structural metals, magnesium metal has been used strategically in key components in automotive, defense and aeronautics since World War II.
Executive Chairman, Mr. Ed Lee, states “This reactor unit is a significant step forward that will enable the Company to enter the marketplace with its proprietary continuous condenser, and will secure Western Magnesium’s future for decades to come.” Initial metal production will allow management to work closely with end users in the automotive, aerospace, and ecofriendly technology companies and the Department of Defense to assess the amount of metal needed for their assembly line manufacturing, and the form in which they will need the metal.
Magnesium prices are rising due to tight supplies from China, by far the world’s largest producer of the rare-earth metal, and brisk demand from the auto industry. Magnesium is mainly used in alloys to strengthen aluminum. While demand for magnesium is growing as automakers work to make their cars lighter, it is also expected to be used in new types of batteries for electric vehicles; according to a report from grandviewresearch.com the global metal magnesium market size was valued at USD 3.5 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 8.8% from 2020 to 2027. Increasing die casting requirements in automotive and various structural applications is projected to assist in the growth of the market for metal magnesium. Magnesium is one of the lightest materials and has an excellent strength to weight ratio. It has high thermal and electrical conductivity and the ability to withstand high operating temperatures. Magnesium alloyed with aluminum is used in various applications including vehicle parts, RFI and EMI shielding, electrical housings, and electrical connectors. Magnesium is critical to the manufacture of car seats, batteries, laptops, plane seats, cell phones, power tools, and auto parts.
$MLYF Strong like Bull…. pic.twitter.com/W56NTK1EA0
— BigWorm (@Unclebuck2323) August 6, 2021
For more on MLYF Subscribe Right Now!
Western Magnesium Corp (OTCMKTS: MLYF) is making a historic rise up the charts in recent months from well under a dime to recent highs near $1 mark. MLYF is quickly emerging as a volume leader in small caps attraction legions of new shareholders including some heavy hitters on the OTC. Currently under heavy accumulation MLYF is moving steadily northbound with many new investors buying in every day. The stock is a powerhouse and continues to move northbound with strength and purpose. The Company is focused on becoming the become world’s low-cost producer of eco-friendly, high-quality magnesium. MLYF has created a proprietary technology which creates a purer form of magnesium in contrast to the Pidgeon process which results in a less pure magnesium. Western Magnesium has just completed the buildout its magnesium reactor. This is a significant, and much anticipated milestone for the Company. Executive Chairman, Mr. Ed Lee, states “This reactor unit is a significant step forward that will enable the Company to enter the marketplace with its proprietary continuous condenser, and will secure Western Magnesium’s future for decades to come.” Initial metal production will allow management to work closely with end users in the automotive, aerospace, and ecofriendly technology companies and the Department of Defense to assess the amount of metal needed for their assembly line manufacturing, and the form in which they will need the metal. Magnesium prices are rising due to tight supplies from China, by far the world’s largest producer of the rare-earth metal, and brisk demand from the auto industry. Magnesium is mainly used in alloys to strengthen aluminum. While demand for magnesium is growing as automakers work to make their cars lighter, it is also expected to be used in new types of batteries for electric vehicles. We will be updating on MLYF when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with MLYF.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in MLYF either long or short and we have not been compensated for this article.
Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.
The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.
To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
$ENVB halted up
— Antonio Costa (@ACInvestorBlog) May 18, 2023
Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.
$ENVB 💰💰💰💰💰 pic.twitter.com/qCIxiCpF0E
— FonsieTrader (@FonsieTrader) May 18, 2023
Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.
$ENVB 👇this is an important milestone for the company! The price could increase fivefold wit the time imo.
Enveric Biosciences Receives Notice Of Allowance From US Patent And Trademark Office For Novel Prodrug Of Psilocin
— Swingy John (@daytrader_2020) May 18, 2023
We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Image by Gino Crescoli from Pixabay
TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million.
Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities
Amgen (NASDAQ: AMGN) and TScan Therapeutics, Inc. (NASDAQ: TCRX) today announced a multi-year collaboration that will use TScan’s proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn’s disease.
All things considered, this is among one of the largest deals you’ll see for a micro-cap biopharma company. As many of you know, companies in this sector of this size and scale are typically not profitable – mainly focusing on R&D until their drug or technology is fully approved/commercially viable.
The critical thing to note with this deal between TScan and Amgen is that the cash milestones ensure a cash runway for TCRX, potentially even until they become commercially viable and profitable.
Here’s a breakdown of the press release in layman’s terms, so anyone without background or knowledge in this space can better understand:
Amgen and TScan Therapeutics are teaming up to find new treatments for Crohn’s disease, a chronic condition that causes inflammation in the gut. TScan has a unique platform called TargetScan that can identify the proteins recognized by the immune system in people with the disease. Amgen will use this information to create new drugs to treat Crohn’s disease.
As part of the deal, TScan will get an upfront payment of $30 million from Amgen and could earn more than $500 million if the collaboration is successful. Amgen will have the rights to develop and sell any new drugs from this partnership.
To Discover the Inside Scoop on TCRX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Both companies will be responsible for their research costs, and Amgen can expand the collaboration to include another condition called ulcerative colitis. This partnership could lead to new and better treatments for people with Crohn’s disease, who currently have limited options for managing their symptoms.
Here are a couple of blurbs from the management team:
“Anti-inflammatory drugs have traditionally been the standard of care for patients suffering from inflammatory bowel disease, but often lack efficacy and durability,” said Raymond Deshaies, Ph.D., senior vice president of Global Research at Amgen. “TScan’s platform provides a best-in-class approach to identify non-conventional drug targets to enable the development of potential first-in-class therapeutics to address unmet medical needs.”
“We’re excited to apply our target discovery platform to the autoimmunity space,” said Gavin MacBeath, Ph.D., acting chief executive officer and chief scientific and operating officer at TScan. “Our TargetScan platform, which we have now extended to identify MHC class II targets of CD4+ T cells, is well-suited for the discovery of antigens targeted by the immune system in inflammatory bowel disease. We look forward to developing the value of our platform both in this partnership with Amgen and in other autoimmune diseases.”
What’s retail saying?
As per usual, with gains of around 135%, you can probably guess that retail is all over it. Investors practically all over the internet keep their eye on the stock for potential entry points utilizing various day trading techniques.
Interestingly, some traders are surprised it managed to trade such massive volumes early intraday. If you look at their chart from the prior months, the average volume was relatively minuscule – sometimes trading as low as 5K shares a day. Compared to the ~27M shares traded at the time of writing, that’s a massive shift.
$TCRX #TCRX nice wake up call watch the break above 5.47 to potential 6.25 test pic.twitter.com/FvoAYEFslG
— APFK_ASIAN PICASSO. (@FLiPTek81) May 9, 2023
$TCRX deserves 1000% 30m upfront 500m contract!
— SHANA (@shanazaman) May 9, 2023
$TCRX ✅✅great earnings 75%gain for me
— Ethio-TradE (@alemcharity) May 9, 2023
$TCRX guess they're not done screwing with people yet. That thing looked dead next thing you know, BAM!
— madaz (@madaznfootballr) May 9, 2023
$LCID massive buyers check orderflow. Count the +ve delta numbers and check sizes. $PLTR $MOBQ $IDEX $CLRO $PYPL $TSLA $FFIE $AMD $TCRX $SOXL $SQQQ $TQQQ $NVAX $PLUG $ENSC $BOIL $XELA $NKLA $CVNA $AAPL pic.twitter.com/d0RaG1xvQl
— Time Traveler Carlssin's Trades (@StockMarketMcro) May 9, 2023
We will update you on TCRX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with TCRX.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Image by Gerd Altmann from Pixabay
On April 27, 2023, shares of ContraFect Corp (NASDAQ: CFRX) skyrocketed by 125% in pre-market trading, which is quite unusual. Although the surge may be linked to the news from the previous day, it is difficult to determine as there was not much movement on April 26.
However, sometimes it only takes the right attention from investors to create such positive rallies. It is worth noting that $CFRX has a low float of 1.53M, which can lead to extreme volatility and provide retail traders an opportunity to make significant gains.
To Find out the inside Scoop on CFRX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Summary of latest PR on April 26, 2023
ContraFect Corporation is a clinical-stage biotechnology company developing new treatments for antibiotic-resistant infections. They recently announced that they initiated a Phase 1b/2 study to test the safety, drug disposition, and efficacy of their drug candidate, Exebacase, in patients with chronic prosthetic joint infections (PJI) of the knee. The study is in France and is randomized, double-blind, and placebo-controlled, meaning some patients will receive the drug, while others will receive a placebo. The study will have two parts: Part I will evaluate the drug’s efficacy, safety, and pharmacokinetics at an early six-week time point, while Part II will assess the long-term clinical safety and efficacy of the drug for up to two years. The CEO of ContraFect Corporation is optimistic about the potential of Exebacase to replace the current surgical treatment for chronic PJI, which has not shown significant improvement in clinical outcomes in recent decades.
What are retail traders saying?
https://twitter.com/RealWillTopol/status/1651553835801001986?s=20
$CFRX
Running in Pre Market Almost +100% From PDC— Avid Trader (@RealAvidTrader) April 27, 2023
$CFRX Why LONG? 🔍👁
Premarket long pattern from the system in room
– dilution above $4
– key level $4
– shorts trapped this early morning
– pullback on trend following
– microfloat + high volumeLive Trading Alerts & Screenshare at https://t.co/ooLvigTt4P #smallcaps… pic.twitter.com/dLX0ZhUwa7
— JTrader (@jtraderco) April 27, 2023
$CFRX $2.12 $2.18 $2.25 if the next low is higher we’re in a good spot!!! https://t.co/axr4eAWTnw pic.twitter.com/k35XYJqQHI
— BULLISHWIRE (@BULLISHWIRE) April 27, 2023
It is worth noting that there has been some speculation about the events that have unfolded and the underlying factors that have led to them.
We’ve observed a subset of traders that capitalize on the volatility by adopting a watchful approach towards stocks, including $CFRX, to generate quick profits.
However, it is essential to exercise caution when considering following their lead, given the high risk associated with their investment strategies and the prevailing market conditions. While we do not typically recommend emulating their investment decisions, it may be an intriguing endeavor for those willing to assume a certain level of financial risk with funds they can afford to lose.
About ContraFect Corp (NASDAQ: CFRX)
ContraFect is a company that focuses on finding new ways to treat life-threatening infections resistant to antibiotics. Antibiotic-resistant infections are responsible for an estimated 700,000 deaths each year worldwide. ContraFect is developing new medical treatments called DLAs that include lysins and amurin peptides. Lysins are antimicrobial proteins that can quickly kill target bacteria, including those in biofilms, and can work with traditional antibiotics. Amurin peptides can fight many antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species. ContraFect believes that lysins and amurin peptides will effectively fight antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections. The company has completed a Phase 2 clinical trial for their lead lysin candidate, exebacase, designated by the FDA as a Breakthrough Therapy for treating MRSA bloodstream infections, including right-sided endocarditis, when combined with traditional antibiotics.
We will update you on CFRX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with CFRX.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Image by Sasin Tipchai from Pixabay
Wearable Devices Ltd. (NASDAQ: WLDS) Breaking Boundaries with AI
CohBar Inc. (NASDAQ: CWBR) and Morphogenesis Join Hands to Create TuHURA Biosciences
Aemetis Inc. (NASDAQ: AMTX) Pioneers Renewable Fuel Market with EPA Approval
Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment
Immutep Limited (NASDAQ: IMMP) Immuno-oncology Breakthrough with Phase 2 Trial Combining Merck & Co’s Keytruda
-
Uncategorized6 months agoMeta Materials Inc (OTCMKTS: MMTLP) Enormous Short Position in Trouble as Next Bridge Hydrocarbons Set to Stop Trading (George Palikaras & John Brda on Corporate Action)
-
Micro Cap Insider2 years agoMedium (KOK PLAY) The Parabolic Rise of Metal Arts (OTCMKTS: MTRT)
-
Media & Technology2 years agoHealthier Choices Management Corp. (OTCMKTS: HCMC) Powerful Comeback Brewing as PMI Patent Infringement Lawsuit Moves Forward
-
Media & Technology2 years ago
AMECA Mining RM; the Rise of Southcorp Capital, Inc. (OTCMKTS: STHC)
-
Media & Technology2 years agoSNPW (Sun Pacific Holding Corp) Power Brewing: 50MW solar farm project in Durango Mexico MOU with Atlas Medrecycler 48,000 SF New Partnership Queensland Australia Solar Farm.
-
BioPharma1 year agoAsia Broadband (OTCMKTS: AABB) On the Move Northbound Since Sub $0.08 Dip as Crypto Innovator Elevates AABB Crypto Exchange & Enters the NFT Space
-
Uncategorized7 months agoMeta Materials Inc (OTCMKTS: MMTLP) Short Squeeze S-1a4 Filing Signals S1 Approval Could Be Days Away (Next Bridge Hydrocarbons Spin-Off)
-
BioPharma2 years agoHumbl Inc (OTCMKTS: HMBL) Major Reversal as Powerful Advisor Rejoins the Team & Looks to Uplist to Major Exchange
